Global Retirement Partners LLC Has $439,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Global Retirement Partners LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,695 shares of the company’s stock after selling 479 shares during the period. Global Retirement Partners LLC’s holdings in Zoetis were worth $439,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC raised its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the period. Darwin Wealth Management LLC bought a new stake in Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis during the third quarter worth approximately $33,000. Finally, Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.9 %

ZTS stock opened at $160.39 on Monday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The stock has a market capitalization of $71.82 billion, a P/E ratio of 29.32, a P/E/G ratio of 2.78 and a beta of 0.90. The business has a fifty day moving average price of $166.51 and a 200-day moving average price of $177.94.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on ZTS shares. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Piper Sandler lowered their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $215.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.